A Multicenter, Open, Single Arm Evaluation of the Efficacy, Safety and Pharmacokinetics of Recombinant Human Coagulation FVIII (SCT800) in Prophylaxis Therapy on Patients With Severe Hemophilia A Who Had Previously Treated With FVIII
Latest Information Update: 27 Sep 2023
At a glance
- Drugs Omfiloctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Sinocelltech
Most Recent Events
- 01 Sep 2021 Results assessing the repeat pharmacokinetics (PKs), efficacy, and safety of SCT800 in previously treated Chinese adolescent and adult patients with severe haemophilia A, published in the Haemophilia
- 04 Feb 2020 Status changed from not yet recruiting to completed.
- 01 Feb 2019 New trial record